WO2007042669A3 - DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl - Google Patents
DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl Download PDFInfo
- Publication number
- WO2007042669A3 WO2007042669A3 PCT/FR2006/002286 FR2006002286W WO2007042669A3 WO 2007042669 A3 WO2007042669 A3 WO 2007042669A3 FR 2006002286 W FR2006002286 W FR 2006002286W WO 2007042669 A3 WO2007042669 A3 WO 2007042669A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkylene
- alkyl
- aryl
- optionally substituted
- nrarb
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 11
- 229910003827 NRaRb Inorganic materials 0.000 abstract 7
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- -1 cycloprop-1,2-diyl Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des dérivés de la 4-amino-quinazoline, de formule générale (I). dans laquelle : A , B = C1-4-alkylène éventuellement substitué ; L = liaison simple, C1-2- alkylène, -CH=CH- ou -C=C- ; les groupes C1-2 alkylene et -CH=CH- étant éventuellement substitués, ou L = cycloprop-1 ,2-diyle ; R = H, C1-5-alkyle, C1-3- fluoroalkyle, C3-6-cycloalkyle, -C(O)C1-3-alkyle, C1-3-alkylène-C3-6--cycIoalkyle, -CH2-C=CH, C2-4-alkylène-NRaRb. C1-3-alkylène-X-C1-3-alkyle où X = O, SO2 ; R1 = aryle ou hétéroaryle ; éventuellement substitués ; R2 et R3 = H, C1-3-alkyle ou C1-3-fluoroalkyle, ou bien R2 et R3 forment ensemble un cycloprop-1 ,1-diyle ; R4 = H, C1-5-alkyle, C1-3- fluoroalkyle, C1-5-alcoxy, -SF5, C1-3-alkylène-X-C1-3-alkyle où X = O ou SO2, C1-5-alkylène- NRaRb. un aryle ou un hétéroaryle éventuellement substitués ; R5 = H, halogène, C1-5- alkyle, 1-3-fluoroalkyle, C1-5-alcoxy, C3-6 cycloalkyle, C1-3 alkylène-C3-6 cycloalkyle, C1-3- alkylène-O-C1-3-alkyle, C1-3-alkylène-(OH), C1.3-alkylène-X-C1-3-alkyle où X = S, SO ou SO2, ou bien R5 = -NRaRb, C1-3 a-alkylèπe-NRaRb, aryle, C1-3-alkylène-aryle, -O-aryle, C1-3- alkylène-O-aryle, C1-3-alkylène-O-C1-3-alkylène-aryle, hétéroaryle ou C1-3-alkylène- hétéroaryle éventuellement substitués, ou R5 = hétérocycle éventuellement substitué par C1-3-alkyle, -C(O)C1-3-alkyle, -C(O)C1-3 fluoroalkyle , C1-3-alkylène-C3-6-cycloalkyle, C1-3- alkylène-aryle, C1-3-alkylène-hétéroaryle éventuellement substitués ; R7 = H, halogène, C1-5 alkyle, C1-3 fluoroalkyle, C1-5 alcoxy, -COOH, (O)O-C1-3-s-alkyle, C1-3 fluoroalcoxy, C1-3-alkylène-(OH), -NO2, -CN, -X-C1-3-alkyle où X représente S, SO ou SO2, ou bien R7 = -NRaRb, C1-3-alkylène-NRaRb, -C(O)-NRaRb -C(O)-C1-3-alkyle, aryle, -O-aryle ou hétéroaryle éventuellement substitués ; à l'état de base ou de sel d'addition à un acide, ainsi qu'à l'état d'hydrate ou de solvat, ainsi que leur procédé de préparation et leur utilisation comme modulateurs des récepteurs MCH 1 pour le traitement de l'obésité, de f anxiété, de la dépression, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0510409A FR2891829A1 (fr) | 2005-10-12 | 2005-10-12 | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
| FR0510409 | 2005-10-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007042669A2 WO2007042669A2 (fr) | 2007-04-19 |
| WO2007042669A3 true WO2007042669A3 (fr) | 2007-05-31 |
Family
ID=36645639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/FR2006/002286 WO2007042669A2 (fr) | 2005-10-12 | 2006-10-11 | DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR056688A1 (fr) |
| FR (1) | FR2891829A1 (fr) |
| TW (1) | TW200732308A (fr) |
| UY (1) | UY29857A1 (fr) |
| WO (1) | WO2007042669A2 (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007283113A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use |
| AU2009249246A1 (en) * | 2008-05-22 | 2009-11-26 | Allergan, Inc. | Bicyclic compounds having activity at the CXCR4 receptor |
| WO2010003624A2 (fr) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Composés hétérocycliques, leurs procédés de préparation, médicaments comprenant lesdits composés et leur utilisation |
| WO2010068601A1 (fr) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| EP2683700B1 (fr) | 2011-03-08 | 2015-02-18 | Sanofi | Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation |
| EP2683705B1 (fr) | 2011-03-08 | 2015-04-22 | Sanofi | Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120053A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation |
| WO2012120052A1 (fr) | 2011-03-08 | 2012-09-13 | Sanofi | Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| AU2017235462B2 (en) | 2016-03-16 | 2021-07-01 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-MLL and methods of use |
| MX388839B (es) | 2016-03-16 | 2025-03-20 | Kura Oncology Inc | Inhibidores sustituidos de menina-mll y metodos de uso |
| US11944627B2 (en) | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
| US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| WO2019060365A1 (fr) | 2017-09-20 | 2019-03-28 | Kura Oncology, Inc. | Inhibiteurs substitués de ménine-mll et méthodes d'utilisation |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984001151A1 (fr) * | 1982-09-24 | 1984-03-29 | Beecham Group Plc | Derives d'amino-azabicycloalkyle utilises en tant qu'antagonistes de la dopamine |
| GB2295387A (en) * | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| WO2003028641A2 (fr) * | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Antagonistes du recepteur de la mch |
| WO2003106452A2 (fr) * | 2002-06-12 | 2003-12-24 | Millennium Pharmaceuticals, Inc. | Antagonistes du recepteur de l'hormone de melano-concentration |
| WO2004052371A2 (fr) * | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Composes de quinoline cycliques utilises avec des troubles lies au recepteur mch |
| WO2004078733A1 (fr) * | 2003-03-03 | 2004-09-16 | Vertex Pharmaceuticals Incorporated | Quinazolines utilisees comme modulateurs de canaux ioniques |
| WO2006071095A1 (fr) * | 2004-12-31 | 2006-07-06 | Sk Chemicals Co., Ltd. | Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité |
-
2005
- 2005-10-12 FR FR0510409A patent/FR2891829A1/fr not_active Withdrawn
-
2006
- 2006-10-11 WO PCT/FR2006/002286 patent/WO2007042669A2/fr active Application Filing
- 2006-10-11 AR ARP060104457A patent/AR056688A1/es not_active Application Discontinuation
- 2006-10-12 UY UY29857A patent/UY29857A1/es unknown
- 2006-10-12 TW TW095137552A patent/TW200732308A/zh unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984001151A1 (fr) * | 1982-09-24 | 1984-03-29 | Beecham Group Plc | Derives d'amino-azabicycloalkyle utilises en tant qu'antagonistes de la dopamine |
| GB2295387A (en) * | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
| WO2003028641A2 (fr) * | 2001-10-01 | 2003-04-10 | Taisho Pharmaceutical Co., Ltd. | Antagonistes du recepteur de la mch |
| WO2003106452A2 (fr) * | 2002-06-12 | 2003-12-24 | Millennium Pharmaceuticals, Inc. | Antagonistes du recepteur de l'hormone de melano-concentration |
| WO2004052371A2 (fr) * | 2002-12-11 | 2004-06-24 | 7Tm Pharma A/S | Composes de quinoline cycliques utilises avec des troubles lies au recepteur mch |
| WO2004078733A1 (fr) * | 2003-03-03 | 2004-09-16 | Vertex Pharmaceuticals Incorporated | Quinazolines utilisees comme modulateurs de canaux ioniques |
| WO2006071095A1 (fr) * | 2004-12-31 | 2006-07-06 | Sk Chemicals Co., Ltd. | Dérivés de quinazoline pour le traitement prophylactique et thérapeutique du diabète et de l'obésité |
Also Published As
| Publication number | Publication date |
|---|---|
| UY29857A1 (es) | 2007-05-31 |
| TW200732308A (en) | 2007-09-01 |
| AR056688A1 (es) | 2007-10-17 |
| FR2891829A1 (fr) | 2007-04-13 |
| WO2007042669A2 (fr) | 2007-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007042669A3 (fr) | DERIVES DE LA 4-AMIN0-QUINAZ0LINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE COMME MODULATEURS DU RECEPTEUR MCHl | |
| WO2009025983A3 (fr) | Procédé pour préparer des dérivés de 5-halogénoalkyl-4,5-dihydroisoxazole | |
| NO20074093L (no) | Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav | |
| WO2007042660A3 (fr) | Dérivés de la 1-amino-phtalazine substituee, leur préparation et leur application en thérapeutique | |
| TW200833690A (en) | 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | |
| WO2006108695A3 (fr) | Composes de sulfoximines macrocycliques et leurs sels, compositions pharmaceutiques comprenant lesdits composes, leurs procedes de preparation et leurs utilisations | |
| WO2009156861A3 (fr) | Dérivés de pyrimidone substitués | |
| EA200501477A1 (ru) | Производные пиперидинил- и пиперазинилалкилкарбаматов, способы их получения и применение их в терапии | |
| JP2009530268A5 (fr) | ||
| WO2010089510A3 (fr) | Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique | |
| TW200637860A (en) | Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same | |
| CO6460742A2 (es) | Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica | |
| WO2008009750A3 (fr) | Composés macrocycliques utiles comme inhibiteurs de la bace | |
| DE60312029D1 (de) | Verfahren zur herstellung c-7 substituierter 5-androstene | |
| TW200617000A (en) | Methods of making 2,6-diaryl piperidine derivatives | |
| WO2008003855A3 (fr) | Utilisation de 2-benzoyl-imidazopyridines en thérapeutique | |
| DE602004004679D1 (de) | Verfahren zur herstellung des hemicalciumsalzes von (e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-ämethyl(methylsulfonyl)aminoüpyrimidin-5-ylü(3r,5s)-3,5-dihydroxy-6-heptensäure | |
| WO2006066957A3 (fr) | Macrocycles sulfonamido et sels de ceux-ci, composition pharmaceutique renfermant ces composes, procede de preparation et utilisation de celle-ci | |
| WO2009106750A3 (fr) | Dérivés 6-heterocyclique-imidazo[1,2-a]pyrroine-2-carboxamides, leur préparation et leur application en thérapeutique | |
| JP2012503653A5 (fr) | ||
| WO2006066044A3 (fr) | Procedes de production de 4-aminoquinazolines | |
| SI1915375T1 (sl) | Derivati 5-piridinil-1-azabiciklo(3.2.1)oktana, njihova priprava in njihova terapevtska uporaba | |
| WO2006066956A3 (fr) | Macrocycles sulfonamido utilises comme inhibiteurs de tie2 et sels de ceux-ci, composition pharmaceutique renfermant ces composes, procede de preparation et utilisation de celle-ci | |
| WO2010067010A3 (fr) | Derives de morphine-6-glucuronide, leur preparation et leur application en therapeutique | |
| DE602006003879D1 (de) | Verfahren zur herstellung von enantiomerenreinen 4-pyrrolidinophenyl- benzyletherderivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06820187 Country of ref document: EP Kind code of ref document: A2 |